Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females

In Vivo

Volumn 28, Issue 4, 2014, Pages 633-638

  Zoga, Margarita ^a   Oulis, Panagiotis ^b   Chatzipanagiotou, Stylianos ^a   Masdrakis, Vasilios G ^b   Pliatsika, Paraskevi ^a   Boufidou, Fotini ^a   Foteli, Stefania ^a   Soldatos, Constantin R ^b   Nikolaou, Chryssoula ^a   Papageorgiou, Charalampos ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antidepressive treatment; IDO; Inflammatory mediators; Major depressive disorder; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CYTOKINE; DIAZEPAM; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; MAJOR DEPRESSION; PATHOPHYSIOLOGY; SEROTONIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SYNTHESIS; TREATMENT DURATION; TRYPTOPHAN METABOLISM; BLOOD; CASE CONTROL STUDY; DEPRESSIVE DISORDER, MAJOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION MEDIATORS; MIDDLE AGED;

EID: 84918512086     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Anisman H: Inflaming depression. Journal of psychiatry & neuroscience: JPN 36: 291-295, 2011.
2. Miller AH, Maletic V and Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65: 732-741, 2009.
3. Raison CL and Miller AH: Is depression an inflammatory disorder? Current Psychiatry Rep 13: 467-475, 2011.
4. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK and Lanctot KL: A meta-analysis of cytokines in major depression. Biological Psychiatry 67: 446-457, 2010.
5. Liu Y, Ho RC and Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affective Disorders 139: 230-239, 2012.
6. Valkanova V, Ebmeier KP and Allan CL: CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affective Disorders 150: 736-744, 2013.
7. Capuron L, Ravaud A, Miller AH and Dantzer R: Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferonalpha cancer therapy. Brain, Behavior, and Immunity 18: 205-213, 2004.
8. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A and Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. Arch General Psychiatry 58: 445-452, 2001.
9. Raison CL, Capuron L and Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31, 2006.
10. Miller AH, Haroon E, Raison CL and Felger JC: Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 30: 297-306, 2013.
11. Russo S, Kema IP, Bosker F, Haavik J and Korf J: Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications. World J Biological Psychiatry 10: 258-268, 2009.
12. Myint AM, Schwarz MJ and Muller N: The role of the kynurenine metabolism in major depression. J Neural Transmission 119: 245-251, 2012.
13. Miura H, Ozaki N, Sawada M, Isobe K, Ohta T and Nagatsu T: A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 11: 198-209, 2008.
14. Mellor AL and Munn DH: Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunology Today 20: 469-473, 1999.
15. Watanabe Y, Fujiwara M, Yoshida R and Hayaishi O: Stereospecificity of hepatic L-tryptophan 2,3-dioxygenase. Biochem J 189: 393-405, 1980.
16. Hayaishi O: Properties and function of indoleamine 2,3- dioxygenase. J Biochemistry 79: 13P-21P, 1976.
17. Stone TW and Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nature Rev Drug Discovery 1: 609-620, 2002.
18. Gal EM and Sherman AD: L-kynurenine: its synthesis and possible regulatory function in brain. Neurochemical Res 5: 223-239, 1980.
19. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B and Myint AM: Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8: 94, 2011.
20. MacKenzie CR, Worku D and Daubener W: Regulation of IDOmediated bacteriostasis in macrophages: role of antibiotics and anti-inflammatory agents. Adv Experimental Med Biol 527: 67-76, 2003.
21. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H and Seishima M: The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochemistry 139: 655-662, 2006.
22. Wichers MC and Maes M: The role of indoleamine 2,3- dioxygenase (IDO) in the pathophysiology of interferon-alphainduced depression. J Psychiatry Neuroscience: JPN 29: 11-17, 2004.
23. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H and Maes M: Increased depressive ratings in patients with hepatitis C receiving interferonalpha- based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacology 22: 86-90, 2002.
24. Gabbay V, Klein RG, Katz Y, Mendoza S, Guttman LE, Alonso CM, Babb JS, Hirsch GS and Liebes L: The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychology Psychiatry, and allied disciplines 51: 935-943, 2010.
25. Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T and Connor TJ: Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain, Behavior Immunity 26: 979-987, 2012.
26. Kim H, Chen L, Lim G, Sung B, Wang S, McCabe MF, Rusanescu G, Yang L, Tian Y and Mao J: Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 122: 2940-2954, 2012.
27. Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schule C, Zill P, Muller N, Rupprecht R and Schwarz MJ: Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain, Behavior Immunity 31: 128-133, 2013.
28. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H and Leonard B: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affective Disorders 98: 143-151, 2007.
29. Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, Mann JJ and Postolache TT: Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain, Behavior Immunity 25: 1272-1278, 2011.
30. Maes M and Rief W: Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 196: 243-249, 2012.
31. Taylor MW and Feng GS: Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5: 2516-2522, 1991.
32. American Psychiatric Association: Diagnostic and statistical manual of mental disorders. Washington, D.C.: American Psychiatric Association, 2000.
33. First MB, Spitzer RL, Gibbon M and Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version Washington, D.C.: American Psychiatric Press, 1997.
34. Leonard B and Maes M: Mechanistic explanations how cellmediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36: 764-785, 2012.
35. Haroon E, Raison CL and Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsycho-pharmacology 37: 137-162, 2012.
36. Chon SY, Hassanain HH and Gupta SL: Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 271: 17247-17252, 1996.
37. Robinson CM, Shirey KA and Carlin JM: Synergistic transcriptional activation of indoleamine dioxygenase by IFNgamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 23: 413-421, 2003.
38. Grant RS, Naif H, Espinosa M and Kapoor V: IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox report. Communications Free Radical Res 5: 101-104, 2000.
39. Pertz H and Back W: Synthesis and resolution of chiral ringopened serotonin analogs of the 5-hydroxykynuramine type. Pharmaceutica Acta Helvetiae 63: 128-131, 1988.
40. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S and Maes M: IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry 10: 538-544, 2005.
41. O'Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW and Dantzer R: Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29: 4200-4209, 2009.
42. Hannestad J, DellaGioia N and Bloch M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36: 2452-2459, 2011.
43. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M and Varga J: Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cellular Physiol 177: 174-186, 1998.
44. Grohmann U, Fallarino F and Puccetti P: Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24: 242-248, 2003.